Table 2.
Adverse effects and the associated risk factors observed after mRNA vaccination in different studies.
| Vaccine | Adverse Effect | Higher Risk Associations Observed | Ref |
|---|---|---|---|
| BNT162b2, mRNA-1273, ChAdOx1 | Myocarditis (in 0.004% of vaccinated participants) | After first dose of BNT162b2 or ChAdOx1. After second dose of mRNA-1273. |
[117] |
| BNT162b2, mRNA-1273, ChAdOx1 | Myocarditis (in 0.007% of vaccinated participants) | After first dose of BNT162b2 or ChAdOx1 After second dose of mRNA-1273. In males under 40 years of age. |
[118] |
| BNT162b2, mRNA-1273 | Myocarditis or pericarditis (rates/million doses: 12.59 and 35.5) | After second dose of mRNA-1273. In males from 18 to 39 years of age. |
[119] |
| BNT162b2, mRNA-1273 | Myocarditis and/or pericarditis (in 0.003% of vaccinated participants) | After second dose of mRNA-1273. In males from 18 to 25 years of age. |
[120] |
| Spikevax | Myocarditis and pericarditis (cases/million doses: 253 and 533) | In males from 18 to 29 years of age. | |
| BNT162b2 | Menstrual cycle symptoms: irregular bleeding (in 23.3% of vaccinated participants), dysmenorrhea (in 68% of vaccinated participants), mood changes (in 9.6% of vaccinated participants) | - | [121] |